Literature DB >> 22246291

Leveraging physiological data from literature into a pharmacokinetic model to support informative clinical study design in pregnant women.

J G Coen van Hasselt1, Bruce Green, Glynn A Morrish.   

Abstract

PURPOSE: Physiological changes during pregnancy can effect pharmacokinetic (PK) parameters, which may lead to altered dose requirements. We aimed to leverage literature-based physiological changes during pregnancy into a PK model and compare its performance to a published reference model in pregnant women and to use the literature-based model to determine informative PK sampling times for a clinical study that aims to quantify the PK of enoxaparin throughout pregnancy.
METHODS: Changes in total body water (BW) and creatinine clearance (CRCL) during pregnancy were described using regression models. BW and CRCL were linked to a PK model of enoxaparin in non-pregnant women. Performance of the literature-based PK model was compared to a previously published empirical reference model. D-optimal sampling times were determined and evaluated for literature-based and reference models.
RESULTS: The literature-based model adequately predicted anti-Xa plasma concentrations when compared to reference model predictions. An informative sampling design was successfully developed, with parameters expected with good precision (RSE < 36.4%).
CONCLUSION: A literature-based model describing enoxaparin PK during pregnancy was developed and evaluated. The modelling framework could be used to support development of informative designs in pregnancy when prior models are unavailable.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22246291     DOI: 10.1007/s11095-012-0671-2

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  27 in total

Review 1.  Drugs in pregnancy. Pharmacokinetics in pregnancy.

Authors:  M Dawes; P J Chowienczyk
Journal:  Best Pract Res Clin Obstet Gynaecol       Date:  2001-12       Impact factor: 5.237

2.  Physiologically based pharmacokinetic model of midazolam disposition during pregnancy.

Authors:  Marilee A Andrew; Mary F Hebert; Paolo Vicini
Journal:  Conf Proc IEEE Eng Med Biol Soc       Date:  2008

Review 3.  Venous thromboembolism during pregnancy.

Authors:  M R Toglia; J G Weg
Journal:  N Engl J Med       Date:  1996-07-11       Impact factor: 91.245

4.  A size standard for pharmacokinetics.

Authors:  N H Holford
Journal:  Clin Pharmacokinet       Date:  1996-05       Impact factor: 6.447

5.  Glomerular filtration during and after pregnancy.

Authors:  J M Davison; F E Hytten
Journal:  J Obstet Gynaecol Br Commonw       Date:  1974-08

6.  Frequency of pregnancy-related venous thromboembolism in anticoagulant factor-deficient women: implications for prophylaxis.

Authors:  P W Friederich; B J Sanson; P Simioni; S Zanardi; M V Huisman; I Kindt; P Prandoni; H R Büller; A Girolami; M H Prins
Journal:  Ann Intern Med       Date:  1996-12-15       Impact factor: 25.391

7.  Some considerations on the design of population pharmacokinetic studies.

Authors:  Stephen Duffull; Tim Waterhouse; John Eccleston
Journal:  J Pharmacokinet Pharmacodyn       Date:  2005-08       Impact factor: 2.745

8.  Cross-sectional study of weight gain and increase in BMI throughout pregnancy.

Authors:  Nicole Ochsenbein-Kölble; Malgorzata Roos; Theo Gasser; Roland Zimmermann
Journal:  Eur J Obstet Gynecol Reprod Biol       Date:  2006-05-12       Impact factor: 2.435

9.  Amoxicillin pharmacokinetics in pregnant women: modeling and simulations of dosage strategies.

Authors:  M A Andrew; T R Easterling; D B Carr; D Shen; M L Buchanan; T Rutherford; R Bennett; P Vicini; M F Hebert
Journal:  Clin Pharmacol Ther       Date:  2007-02-28       Impact factor: 6.875

Review 10.  Thromboprophylaxis in medical patients: focus on France.

Authors:  Jean-François Bergmann; Stéphane Mouly
Journal:  Semin Thromb Hemost       Date:  2002-08       Impact factor: 4.180

View more
  4 in total

Review 1.  Optimizing drug development of anti-cancer drugs in children using modelling and simulation.

Authors:  Johan G C van Hasselt; Natasha K A van Eijkelenburg; Jos H Beijnen; Jan H M Schellens; Alwin D R Huitema
Journal:  Br J Clin Pharmacol       Date:  2013-07       Impact factor: 4.335

Review 2.  The status of pharmacometrics in pregnancy: highlights from the 3(rd) American conference on pharmacometrics.

Authors:  J G Coen van Hasselt; Marilee A Andrew; Mary F Hebert; Joel Tarning; Paolo Vicini; Donald R Mattison
Journal:  Br J Clin Pharmacol       Date:  2012-12       Impact factor: 4.335

3.  Semiphysiological versus empirical modelling of the population pharmacokinetics of free and total cefazolin during pregnancy.

Authors:  J G Coen van Hasselt; Karel Allegaert; Kristel van Calsteren; Jos H Beijnen; Jan H M Schellens; Alwin D R Huitema
Journal:  Biomed Res Int       Date:  2014-02-03       Impact factor: 3.411

4.  Perinatal pharmacology.

Authors:  Karel Allegaert; Vassilios Fanos; Johannes N van den Anker; Stephanie Laër
Journal:  Biomed Res Int       Date:  2014-04-13       Impact factor: 3.411

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.